In the past week, PHIO stock has gone down by -0.31%, with a monthly decline of -19.75% and a quarterly plunge of -17.14%. The volatility ratio for the week is 12.47%, and the volatility levels for the last 30 days are 10.66% for Phio Pharmaceuticals Corp The simple moving average for the past 20 days is -10.55% for PHIO’s stock, with a -50.06% simple moving average for the past 200 days.
Is It Worth Investing in Phio Pharmaceuticals Corp (NASDAQ: PHIO) Right Now?
Additionally, the 36-month beta value for PHIO is 1.48. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PHIO is 0.83M and currently, short sellers hold a 6.20% ratio of that float. The average trading volume of PHIO on November 20, 2024 was 62.79K shares.
PHIO) stock’s latest price update
Phio Pharmaceuticals Corp (NASDAQ: PHIO)’s stock price has gone rise by 12.42 in comparison to its previous close of 2.27, however, the company has experienced a -0.31% decrease in its stock price over the last five trading days. newsfilecorp.com reported 2024-11-19 that –Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts–(Newsfile Corp. – November 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a cancer-free future, today announced it has completed the enrollment of its second patient cohort in its PH-762 Phase 1b dose-escalating clinical trial, and added a sixth clinical site in San Diego, CA. Phio recently presented new data from the ongoing clinical trial showing that, of the two patients who have completed treatment in the second dose cohort, one patient with cutaneous squamous cell carcinoma achieved a complete response (100% tumor clearance) while a second patient with squamous cell carcinoma achieved a partial response (90% tumor clearance).
Analysts’ Opinion of PHIO
Many brokerage firms have already submitted their reports for PHIO stocks, with H.C. Wainwright repeating the rating for PHIO by listing it as a “Buy.” The predicted price for PHIO in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on August 05, 2020 of the previous year 2020.
PHIO Trading at -15.89% from the 50-Day Moving Average
After a stumble in the market that brought PHIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.43% of loss for the given period.
Volatility was left at 10.66%, however, over the last 30 days, the volatility rate increased by 12.47%, as shares sank -18.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.67% lower at present.
During the last 5 trading sessions, PHIO fell by -0.39%, which changed the moving average for the period of 200-days by -51.61% in comparison to the 20-day moving average, which settled at $2.85. In addition, Phio Pharmaceuticals Corp saw -62.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHIO starting from Bitterman Robert J, who purchase 1,000 shares at the price of $0.74 back on Jun 07 ’24. After this action, Bitterman Robert J now owns 20,990 shares of Phio Pharmaceuticals Corp, valued at $740 using the latest closing price.
Bitterman Robert J, the President & CEO of Phio Pharmaceuticals Corp, purchase 1,000 shares at $0.75 during a trade that took place back on Jun 06 ’24, which means that Bitterman Robert J is holding 19,990 shares at $750 based on the most recent closing price.
Stock Fundamentals for PHIO
Current profitability levels for the company are sitting at:
- -196.53 for the present operating margin
- -1.6 for the gross margin
The net margin for Phio Pharmaceuticals Corp stands at -247.3. The total capital return value is set at -1.19. Equity return is now at value -122.03, with -96.33 for asset returns.
Currently, EBITDA for the company is -10.64 million with net debt to EBITDA at 0.94. When we switch over and look at the enterprise to sales, we see a ratio of -89.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.38.
Conclusion
In conclusion, Phio Pharmaceuticals Corp (PHIO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
